UBS Reaffirms Buy Rating for Elevance Health Amid Improved Industry Trends
On May 22, UBS upgraded its price target on Elevance Health (NYSE:ELV) to $460 from $400 and reaffirmed a 'Buy' rating. The firm cited stronger-than-expected Q1 results driven by favorable respiratory trends and seasonal cost patterns, along with improved confidence in margin recovery due to better Medicare Advantage rates and steadier ACA enrollment.
Tickers: $ELV
Topics: Elevance Health Managed Care Industry Stock Ratings UBS